---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-009312"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:05:44.364732+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences Q1 net loss $11.8M; CAHmelia-203 25% enrolled; debt facility amended

## Summary
- Net loss $11.8M in Q1 2022 vs $9.9M in Q1 2021; cash and investments $108.9M as of March 31, 2022.
- CAHmelia-203 adult classic CAH study reached 25% enrollment; topline data on track for 2H 2023.
- Amended SVB debt facility provides up to $10M credit line in 2022; interest rate cut 50-250 bps.
- Appointed Libbie Mansell, Ph.D., as Chief Regulatory and Quality Officer in April 2022.
- Tildacerfont patent portfolio expanded with two new U.S. method-of-use patents expiring 2038.

## SEC filing metadata
- accession: 0000950170-22-009312
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017022009312/0000950170-22-009312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017022009312/sprb-20220511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-009312
- JSON: https://secwatch.observer/filing/0000950170-22-009312.json
- Plain text: https://secwatch.observer/filing/0000950170-22-009312.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.